Press Room


    Press Release - February 12, 2002

    Pheromone Sciences Corp Reports Positive Trial Results on Fertility Monitor

    Pheromone Sciences Corp (CDNX: PHS), is pleased to announce that it has received positive results from its PSC Fertility Monitor�¢ï¿½�¢ U.S. clinical trial.

    The trial, which enrolled 105 subjects, was carried out at Duke University, Durham, N.C., under the direction of Dr. A. Haney Professor of Obstetrics and Gynecology of Duke University and Dr. Stephen Corson Professor, Obstetrics and Gynecology at The Women's Institute of Fertility, Sterility and Menopause, Thomas Jefferson University Medical School in Philadelphia. Results showed that 73% of the ovulatory women had their ovulation date correctly predicted to within +/-2 days of the ovulation date determined by blood serum levels. These results are consistent with those previously reported (76%) from a pilot study conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto.

    As expected, due to the product's non-invasive nature, no safety or side effects issues were reported throughout the trial.

    Based on these results, the Company will, within 30 days, file a 510K submission to the FDA for marketing approval of the Fertility Monitor in the United States.

    It is well recognized by the medical community that conception occurs when sexual intercourse occurs within a 6 day period starting approximately four to five days before ovulation. The PSC Fertility Monitor confirmed its unique ability to predict a women's fertility window. Discreetly housed within a wristwatch-like device that is worn during sleeping hours, the PSC Fertility Monitor offers women an easy to use, non-invasive means of obtaining advance notice of their fertility window.

    "Based upon the data analysis of the patients who completed the trial, the PSC Fertility Monitor detected more days of the conception window (the days when sexual intercourse can lead to a pregnancy) than the LH test strip product. This determination, coupled with the published literature on the chances of conception during this window (Wilcox, New England Journal of Medicine), strongly suggests that women who use the PSC Fertility Monitor as a means of identifying their fertile window to time intercourse, can expect a substantially higher probability of conception or a substantially shorter time to pregnancy than if they relied solely on home based LH test kits as a means to time intercourse," said Dr. A. Haney, Professor of Obstetrics and Gynecology of Duke University. "This is based upon the PSC Fertility Monitor's unique ability to identify the 6 day fertility window with up to a four day advance notice of the predicted ovulation day. For women who are seeking to become pregnant, the PSC Fertility Monitor would seem to offer some unique advantages in helping these women to discover their entire fertility window."

    As a non-invasive device designed for in-home testing to identify the complete fertility window without the inconvenient and unpleasant use of urine or blood samples, the PSC Fertility Monitor offers a new level of convenience, ease of use and the knowledge that the entire fertility window is now easily identified," said Dr. Stephen Corson, Professor, Obstetrics and Gynecology at The Women's Institute of Fertility, Sterility and Menopause, Thomas Jefferson University Medical School in Philadelphia.

    "Providing the ability to utilize more of the fertility window is an element that will aid women wishing to conceive", said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "Combining advance notice along with convenience and ease of use, make this a product we believe women will embrace".

    Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

    Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.


    Lorne Woods 1-(800) 937-3095


    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News